The Phase III AGILE trial expanded the role of IDH-targeted therapy, demonstrating that the combination of azacitidine and ivosidenib significantly improved event-free and median overall survival compared to azacitidine alone in newly diagnosed patients with IDH1-mutant AML who were ineligible for intensive chemotherapy (24.0 months vs. 7.9 months) (12) [31]. This evidence concerns the gene IDH2 and acute myeloid leukemia.